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Background: Inequalities in the use of new medications may contribute to health disparities. 
We analyzed socioeconomic gradients in the use of tiotropium for chronic obstructive pulmo-
nary disease (COPD).
Methods: In a cohort of adults with COPD aged 55 years identiﬁ  ed through population-based 
sampling, we elicited questionnaire responses on demographics, socioeconomic status (SES; 
lower SES deﬁ  ned as high school education or less or annual household income US $20,000), 
and medication use and other clinical variables. In a subset we obtained pulmonary function test-
ing. We used multiple logistic regression analysis to estimate the associations between SES and 
tiotropium use in COPD, adjusting for disease severity measured by a COPD Severity Score.
Results: Of 427 subjects, 44 (10.3%) reported using tiotropium in 2006. Adjusting for COPD 
severity, lower SES was associated with reduced odds of tiotropium use (OR 0.3; 95% CI 
0.1–0.7; p = 0.005). Among the subset with lung function data (n = 95), after including COPD 
Global Obstructive Lung Disease (GOLD) Stage 2 in the model, lower SES remained associ-
ated with reduced odds of tiotropium use (OR 0.03; 95% CI  0.001–0.7; p = 0.03). Including 
forced expiratory volume in one second in the model as a continuous variable instead of GOLD 
Stage 2 yielded similar results for lower SES (OR 0.1; 95% CI  0.001–0.5; p = 0.02).
Conclusion: There was a strong SES gradient in tiotropium use such that there was less use 
with lower SES. To the extent that this is an efﬁ  cacious medication for COPD, this gradient 
represents a potential source of health disparities.
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Introduction
The introduction of novel and efﬁ  cacious medications can be a major factor in reduced 
disease morbidity and mortality on a population-wide basis. The salutatory health 
impact of such innovations, however, depends on availability and use of the drug 
among those for whom such use is medically indicated and a beneﬁ  t is anticipated. 
Health disparities in disease prevalence and severity remain a major public health issue 
in the US, despite an enormous expenditure of resources on health care generally and 
prescription pharmaceuticals in particular (Warren and Hernandez, 2007; Adler and 
Rehkopf 2008). The role that socioeconomic status (SES) may play in potential health 
disparities related to the use of newly approved prescription drugs could be especially 
relevant to this question, but has not been well studied.
Tiotropium, a long-acting analogue of the inhaled anticholinergic medication 
ipratropium bromide introduced in the US in 2004, is one example of a relatively new 
pharmaceutical with rapid dissemination in prescribing (Anon 2004). The approved 
indication for tiotropium use is chronic obstructive lung disease (COPD), a relatively 
common and potentially life-threatening condition. COPD is causally associated 
with cigarette smoking and with adverse working conditions, both of which, in turn, 
manifest strong SES gradients (Mannino and Buist 2007). It can be anticipated that many of those most likely to beneﬁ  t from this medication’s 
introduction are of lower SES. Thus any SES gradient in 
tiotropium use in treating COPD could be especially relevant 
to the broader question of new pharmaceutical-related SES 
gradients in health.
SES gradients in tiotropium use were examined among 
our COPD cohort. Using data from 2006 interviews after 
tiotropium was relatively new in the market but its use was 
well established, we analyzed the association between SES 
and tiotropium use, taking into account disease severity.
Methods
Overview
We used structured interview data from a single wave of a 
longitudinal study in a cohort of older adults with airway 
disease. Although the total cohort includes persons with other 
airway disease diagnoses, we limited this analysis to those 
who reported receiving at least one of three COPD-deﬁ  ning 
physician diagnoses: COPD, emphysema, or chronic bronchi-
tis. Interviews assessed demographics and extensive health-
related data, including a detailed respiratory medication 
check-list. A subset of subjects also participated in home visits 
in which spirometry measurements were obtained. The a pri-
ori goals of the parent study from which we drew are data were 
to assess occupational and nonoccupational impairments 
and health outcomes in lung disease. Because one wave of 
interviews were carried out following the introduction of a 
new COPD prescription medication in the United States, we 
saw an opportunity to examine factors associated with the 
use of this drug. Speciﬁ  cally, we analyzed self-reported use 
of tiotropium in relation to demographics and COPD-related 
covariates. All key analyses were carried out for all COPD 
subjects together and then repeated excluding subjects who 
only reported chronic bronchitis, in order to evaluate whether 
exclusion of this COPD-related diagnosis affected our risk 
factor estimates. The study was approved by the University 
of California SF Committee on Human Research.
Subject recruitment and retention
We used cross-sectional data from the 2006 interview Wave 
5 only of a population-based, multi-wave longitudinal cohort 
study of US adults with airways disease that includes a subset 
of persons with COPD. The details of subject recruitment 
and retention over ﬁ  ve waves of interview history from 2001 
through 2006 are summarized in Figure 1. Analyses based 
on earlier interview waves have been reported previously 
(Trupin et al 2003; Blanc et al 2004; Chen et al 2006). The 
427 interviews used in this analysis included 136 persons 
with COPD retained through four previous interview waves 
and 291 persons with COPD newly recruited.
Interview structure and content
The same questionnaire was administered to all subjects in 
the 2006 interviews used in this analysis. Structured inter-
views were performed by trained personnel using computer-
assisted telephone interviewing (CATI) software. Interviews 
queried demographics, smoking, and respiratory condition 
variables such as symptoms, health care utilization (including 
subspecialty care by a pulmonary, allergy, or otolaryngology 
provider in the previous 12 months), insurance coverage for 
medication costs (none, some, or all costs covered), supple-
mental oxygen use, and an extensive checklist of respiratory 
medications used at any time in the pervious two weeks. 
These medications included various speciﬁ  c brands and 
generic forms of corticosteroids (oral and inhaled), short- 
and long-acting beta agonists, corticosteroid-beta agonist 
combinations, ipratropium bromide, and tiotropium. Where 
appropriate to efﬁ  ciently elicit interview responses, brand 
names were queried. This included “Spiriva®” for the generic 
medication tiotropium.
We used interview data to calculate COPD Severity Score 
values for each subject (Eisner et al 2005, 2007). This vali-
dated measure uses a weighted algorithm to score multiple 
components: recent symptoms, current medications, home 
supplemental oxygen use, past systemic corticosteroid and 
antibiotic use, and prior hospitalizations and mechanical 
ventilatory support for respiratory disease. The possible 
range is 0 to 35 points; standard deviation is approximately 
8 points in magnitude; and higher scores indicate greater 
COPD severity. Because the standard COPD Severity Score 
includes a one point weighting for tiotropium use, for this 
analysis we omitted that component so that COPD severity 
could be analyzed independent of such use.
Medication veriﬁ  cation and spirometric 
assessment
A subset of subjects participated in home visits during 
which medications were conﬁ  rmed by direct inspection and 
spirometry was assessed. To be eligible for home visits, sub-
jects must have resided in northern California at the time of 
their telephone interviews. From among those geographically 
eligible, we attempted to recruit an approximate 50% sample 
for Wave 5 home visits. There were 101 (24%) of 427 sub-
jects with COPD who ultimately participated in spirometry 
testing carried out in home visits following their Wave 5 
interviews. The time interval elapsed between interview and 
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Medication use was conﬁ  rmed by requesting that subjects 
show to the home study team all respiratory medications.
Spirometry was performed using an EasyOne™ Spi-
rometer (ndd Medical Technologies, Chelmsford, MA). 
This instrument has been used widely in ﬁ  eld studies of 
COPD (Menezes et al 2005; Buist et al 2007). Spirometry 
measurements, including the forced expiratory volume in 
one second (FEV1) and forced vital capacity (FVC) were 
performed conforming to American Thoracic Society guide-
lines (Miller et al 2005). Subjects did not perform testing 
following study-administered bronchodilators; they were 
told to take their normal bronchodilator medicines according 
to their routine schedule on the day of the home visit. We 
used standard predictive equations to calculate age, height, 
and sex predicted FEV1 % predicted values (Hankinson et al 
Figure 1 Recruitment and retention of study subjects.
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Wave 1
(2001)
National sample
17,442 households contacted
2,281 confirmed adult 55-75
1,001 completed interview
Hot spot sample
16,042 households contacted
1,933 confirmed adult 55-75
1,002 completed interview
Respiratory condition sample
7,853 households contacted
1,193 confirmed adult 55-75
210 confirmed condition
110 completed interview
2,113 Interviewed
(53% of eligible)
Wave 2
(2002)
113 (22%) refused
8 (2%) died
44 (9%) lost to follow-up
Wave 3
(2003)
323 from Wave 1 w/ sleep 
apnea, allergic rhinitis 
675 eligible
433 (64%) re-interviewed
204 COPD
229 asthma,
       other
352 (68%) re-nterviewed
267 COPD
85 asthma
Wave 4
(2004)
517 COPD or asthma
386 COPD
131 asthma
373 (86%) interviewed
173 COPD
200 asthma,
       other
33 (8%) refused
8 (2%) died
15 (3%) lost to follow-up
139 (21%) refused
9 (1%) died
92 (14%) lost to follow-up
Wave 5
(2006)
299 (80%) re-interviewed
136 COPD
163 asthma,
       other
40 (11%) refused
16 (4%) died
18 (5%) lost to follow-up
674 interviewed
427 COPD
247 asthma,
       other
New Cohort
20,247 households contacted
5,934 confirmed adult 55-75
701 confirmed condition
375 completed interview
(53% of eligible)
(291 COPD, 84 asthma)1999). We used Global Obstructive Lung Disease (GOLD) 
criteria (although not post-bronchodilator values) to deﬁ  ne 
COPD as Stage II or above (FEV1 % predicted <80%; FEV1 
to FVC ratio <70%) (GOLD 2006).
Data analysis
We tested differences in subject characteristics between tiotro-
pium users and nonusers using the chi-square, Fisher’s exact 
test, or Student’s t-test. We used multiple logistic regression 
analysis to test the associations between low SES (using the 
measures of educational achievement of a high school educa-
tion or less [HS]) or HS or an annual household income of 
less than US $20,000) and the use of tiotropium. All models 
also included age, sex, and indicator variables for each of 
up to three reported physician’s COPD condition diagnoses 
(COPD, emphysema, chronic bronchitis; overlapping, mul-
tiple reported diagnoses were possible). In addition, subjects 
could also report asthma as a condition if this was concomitant 
with at least one of the COPD diagnoses (those with asthma 
alone were excluded from this analysis). Therefore, we also 
included asthma as a separate condition indicator variable.
Additional models included COPD Severity Score. All 
key analyses were rerun excluding subjects who reported 
chronic bronchitis as their sole COPD condition. As another 
test of possible confounding we also re-analyzed our main 
COPD Severity Score models adding the following addi-
tional variables: race-ethnicity (White non-Hispanic vs. 
all others); regional U.S. geographic location (Northern 
California vs. all others); access to subspecialty care (visit 
to a pulmonary, allergy or otolaryngology specialist in 
the previous 12 months); and any insurance coverage of 
medication costs (any vs. none). We retested multiple logistic 
regression models including all of these predictors in the 
subset of subjects for whom spirometry data were available. 
We did this in two ways: adding to the previous models 
FEV1 % predicted as a continuous independent variable and, 
alternatively, entering GOLD Stage II or above COPD as a 
dichotomous predictor variable.
Results
Table 1 shows the distribution of key demographic and clini-
cal variables, for the entire study cohort and after excluding 
207 subjects who reported chronic bronchitis alone without 
either concomitant COPD or emphysema. Even among the 
latter group, tiotropium use was reported by fewer than 1 in 
5 subjects. The two measures of lower SES of interest (HS 
education or less and annual household income <$20,000) 
were well represented among study subjects and were 
Table 1 Demographic and medical characteristics among study cohort
Characteristic  COPD, emphysema or chronic bronchitis [n = 427]  COPD or emphysema* [n = 240]
Female gender  266 (62%)  139 (58%)
Age >65 Years  227 (53%)  147 (61%)
White, non-Hispanic  366 (86%)  205 (85%)
High school education or less (HS)  138 (32%)  95 (40%)
Annual household income <$20,000†  106 (26%)  65 (29%)
HS or income <$20,000  189 (44%)  120 (50%)
Lives in northern Californian region  305 (71%)  175 (73%)
Cigarette smoking status   
Former  240 (56%)  150 (63%)
Current  94 (22%)  66 (28%)
Never  93 (22%)  24 (10%)
Respiratory diagnosis‡  
COPD 146  (34%)  146  (61%)
Emphysema  166 (39%)  166 (69%)
Chronic bronchitis  304 (71%)  117 (49%)
Concomitant asthma‡  215 (50%)  123 (51%)
Home oxygen use  72 (17%)  65 (27%)
Inhaled or oral corticosteroid use  103 (24%)  78 (33%)
Long-acting beta agonist use  108 (25%)  85 (35%)
Some medication insurance coverage  389 (91%)  216 (90%)
Medical subspecialist treatment¶  130 (30%)  91 (38%)
Tiotropium use  44 (10%)  41 (17%)
Notes: *Bronchitis alone without concomitant COPD or emphysema excluded; †Income data missing for 22 of 427 subjects in entire study group; 13 of 240 subjects in COPD/
emphysema stratum; ‡Multiple diagnoses can be reported. For asthma, a concomitant diagnosis of COPD, emphysema, or chronic bronchitis must be reported; ¶ Treatment in 
the past 12 months by a pulmonary, allergy, or otolaryngology specialist.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Table 2 Subject demographics, clinical status, and tiotropium use
COPD, emphysema, or chronic bronchitis (n = 427)
Subject characteristic  Tiotropium use (%)  P value
   if Subject 
   characteristic…
   Present  Absent 
Female gender  11%  9%  0.49
Age 65 years  13%  7%  0.05
White, non-Hispanic  11%  7%  0.37
High school education   11%  10%  0.92
or less (HS)
Annual household income   7%  11%  0.26
$20,000*
HS or household income   9%  11%  0.53
$20,000
Respiratory diagnosis†    
COPD 19%  6%  <0.001
Emphysema 20%  4%  <0.001
Chronic bronchitis  9%  14%  0.18
Concomitant asthma  13%  7%  0.04
Home supplemental  
oxygen use  32%  6%  <0.001
Inhaled or oral corticosteroid   16%  9%  0.07
use
Long-acting beta agonist use  29%  4%  <0.001
Medical subspecialist treatment‡ 18%  7%  0.002
COPD or emphysema† (n = 240)
Subject characteristic  Tiotropium use (%)  P value
   if Subject 
   characteristic…
   Present  Absent
Female gender  19%  14%  0.34
Age 65 years  20%  13%  0.23
White, non-Hispanic  18%  11%  0.48
High school education   15%  19%  0.54
or less (HS)
Annual household income   9%  19%  0.10
$20,000*
HS or household income   12.5%  22%  0.09
$20,000
Respiratory diagnoses†    
COPD 19%  14%  0.37
Emphysema 20%  11%  0.12
Chronic bronchitis  21%  14%  0.23
Asthma 21%  13%  0.12
Home supplemental oxygen use  34%  11%  <0.001
Inhaled or oral corticosteroid use  18%  17%  0.95
Long-acting beta agonist use  34%  8%  <0.001
Medical subspecialist treatment‡ 23%  13%  0.08
Notes: All proportions are presented as row percentages; *Income data missing for 
22 of 427 subjects in entire study group; 13 of 240 subjects in COPD/emphysema 
stratum; †Multiple respiratory conditions can be reported; for asthma, a concomitant 
COPD condition must be reported to be included; ‡Treatment in the past 12 months 
by a pulmonary, allergy, or otolaryngology specialist.
Abbreviation: COPD, chronic obstructive pulmonary disease.
inter-related. Among 405 with income data, 51 (19%) of 275 
with more than a HS education reported annual household 
incomes <$20,000, compared with 55 (42%) of 130 with HS 
or less (p < 0.001). Altogether 189 (44%) of subjects had 
either attained HS or less education or reported <$20,000 
income (14 subjects with greater than HS education were in 
the missing income group and were dichotomized as higher 
SES by this measure).
In unadjusted analyses (Table 2), the only demographic 
variable statistically signiﬁ  cantly associated with tiotropium 
use was older age: 13% of subjects over age 65 reported 
tiotropium use compared to 7% of those 65 or younger 
(p = 0.05). Tiotropium use was related to each co-morbid 
respiratory diagnosis, except for chronic bronchitis. Home 
supplemental oxygen (home O2) was strongly associated with 
tiotropium use. Even among home O2 users, only one-third 
reported using tiotropium. Long-acting beta agonist (LABA) 
use had a similar pattern to that of home O2 with tiotropium. 
Those treated by subspecialists were more likely to report 
tiotropium use (p = 0.002). As shown in the lower portion 
of Table 2, among the subset of subjects reporting COPD or 
emphysema (n = 240; excludes subjects with chronic bron-
chitis as their sole COPD-deﬁ  ning condition), tiotropium use 
did not differ statistically by demographic variables or by any 
respiratory condition. In this subset of subjects, however, 
home O2 and LABA use remained statistically associated 
with tiotropium use, while subspecialty care was less strongly 
associated in this subset (p = 0.08).
COPD Severity Score, a measure including use of supple-
mental home O2, LABA, steroid use, and other medications, as 
well as symptoms, differed by tiotropium status: 6.9 (SD 5.9) 
(nonusers) compared to 14.2 (SD 5.7) for tiotropium users 
(p < 0.001). COPD Severity Score also differed signiﬁ  cantly 
by tiotropium status in the COPD or emphysema subset: 8.8 
(SD 6.6) v. 14.1 (SD 5.6) (p < 0.001). Comparing those with 
SES deﬁ  ned by either HS education or lower income to all 
others, lower SES was associated with greater COPD severity 
(mean score difference = 2.8 [SE 0.6]; p < 0.001). Among the 
COPD/emphysema subset, this difference was similar (mean 
score difference = 2.7 [SE 0.9]; p < 0.001).
Table 3 shows the association between tiotropium use 
and lower SES by two measures (HS education alone and 
HS and/or lower income). Multivariate models are pre-
sented for the entire study group and re-estimated among 
the COPD/emphysema subset. In Model One (unadjusted 
for COPD Severity Score), selected respiratory condition 
diagnoses are associated with tiotropium use while lower 
SES is not. When COPD Severity Score is added (Models Two and Three), lower SES is associated with decreased 
odds of tiotropium use. Those with lower SES, taking 
disease severity into account, have one third to half the odds 
of reporting tiotropium use. Adjusting for severity, which 
was strongly associated with tiotropium use, also blunted 
the respiratory condition effects seen in Model One. In this 
model, emphysema was associated with a three- to four-fold 
increased odds of tiotropium use.
In order to take into account other potential confounders, 
we reanalyzed the data adding to model three variables for 
race-ethnicity, geographic region, subspecialty care, and 
at least some medication cost coverage through insurance. 
The covariates for respiratory condition, COPD Severity 
Score, age, and gender were also included. None of the 
added variables was statistically associated with tiotropium 
use either among the entire group (n = 427) or in the subset 
excluding chronic bronchitis alone (n = 240). The association 
between lower SES and tiotropium in these models was not 
substantively different from the results from the simpler model 
(Model Three) as shown in Table 3: for the whole group, OR 
0.3, 95% CI 0.1–0.7 (p = 0.004); for the subset without chronic 
bronchitis alone, OR 0.2, 95% CI 0.1–.6 (p = 0.002).
There were home visit data for 101 of these subjects. 
Of 12 subjects with home visits who reported use of tiotro-
pium in the telephone interview, this was conﬁ  rmed by 
direct inspection of medications among 9 subjects. There 
were also 3 additional subjects who did not report use in 
the interview but did have tiotropium among their medica-
tions. Using medication inspection as the gold standard, the 
interview checklist for tiotropium had a sensitivity of 75% 
and a speciﬁ  city of 97%. Excluding the six respondents with 
discordant tiotropium data, among the remaining 95 subjects 
the mean FEV1 % predicted for tiotropium users was 62.4% 
(SD 20.6%) compared to 86.1% (SD 18.6%) among the 
nonusers (p < 0.001). Analyzed by COPD stage GOLD II or 
more, tiotropium use also differed signiﬁ  cantly. Of 35 with 
Table 3 Tiotropium use in relation to reported respiratory diagnoses, disease severity, and socioeconomic status (SES): Multiple logistic 
regression analysis
  COPD, emphysema, chronic bronchitis   COPD or emphysema† 
 (n  = 427)    (n = 240)
MODEL ONE¶  Tiotropium use
  OR  95% CI (p value)  OR  95% CI (p value)
Respiratory conditions*       
COPD  2.6  1.3–5.3 (0.007)  1.7  0.7–4.0 (0.21)
Emphysema 5.9  2.7–13  (0.001) 3.4  1.4–8.7  (0.01)
Chronic bronchitis  1.1  0.5–2.3 (0.80)  1.4  0.7–3.0 (0.36)
Concomitant asthma  2.1  1.0–4.4 (0.05)  1.9  0.9–4.0 (0.11)
≤HS education  0.7  0.3–1.4 (0.29)  0.6  0.3–1.3 (0.17)
MODEL TWO¶  Tiotropium use
  OR  95% CI (p value)  OR  95% CI (p value)
Respiratory conditions*       
COPD 1.7  0.8–3.7  (0.16)  1.2  0.5–3.1  (0.63)
Emphysema 4.5  1.9–10.4  (0.001) 2.9  1.1–7.8  (0.03)
Chronic bronchitis  0.8  0.4–1.8 (0.64)  1.1  0.5–2.6 (0.88)
Concomitant asthma  1.6  0.7–3.5 (0.25)  1.4  0.6–3.2 (0.39)
COPD Severity Score  2.9‡ 1.9–4.6  (0.001) 2.6‡ 1.6–4.1  (<0.001)
≤HS education  0.5  0.2–1.04 (0.06)  0.4  0.2–0.96 (0.04)
MODEL THREE¶  Tiotropium use
  OR  95% CI (p value)  OR  95% CI (p value)
Respiratory conditions*       
COPD 1.6  0.9–4.5  (0.20)  1.1  0.5–2.9  (0.78)
Emphysema 4.2  1.8–9.7  (0.001) 2.7  1.0–7.2  (0.05)
Chronic bronchitis  0.8  0.4–1.7 (0.54)  1.0  0.5–2.3 (0.98)
Concomitant asthma  1.6  0.7–3.5 (0.27)  1.4  0.6–3.3 (0.39)
COPD Severity Score  3.3‡ 2.1–5.4  (0.001) 3.0‡ 1.8–5.0  (0.001)
HS education or income $20,000 0.3  0.1–0.7  (0.005)  0.3  0.1–0.6  (0.002)
Notes: *Each respiratory condition entered as a separate dummy variable. Condition diagnoses may overlap; †Bronchitis alone without concomitant COPD or emphysema 
excluded; ‡OR expressed per 8 point (1 SD) severity score; ¶Model Two adds COPD Severity Score to the variables in Model One. Model Three substitutes ≤HS education or 
income <$20,000 for ≤HS education alone. All multivariate models also include age and gender.
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, conﬁ  dence interval; HS, high school; Income, annual household income; OR, odds ratio.
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at the time of our survey provided no outpatient medication 
beneﬁ  ts, the cost of tiotropium may have led to decreased 
use among those with low SES without supplemental medi-
cation coverage, with insurance formulary restrictions, or 
with high medication co-payments. We did not have speciﬁ  c 
data on the amounts of insurance co-pays for medication or 
medication out-of-pocket costs and thus could not include 
this in our analysis, although we did not ﬁ  nd that absence of 
any medication insurance coverage was related to tiotropium 
use. Because most of our subjects did have some coverage, 
we may not have had sufﬁ  cient power to study this question. 
A recent study found that the Medicare Modernization Act 
Prescription Drug Beneﬁ  t (Part D) was associated with a very 
modest increase in utilization and savings in out-of-pocket 
costs (Yin et al 2008).
The deterrent effect of out-of-pocket costs is consistent 
with the observation that elderly patients with COPD who 
are reimbursed only for generic medications (compared 
to those with greater coverage) have an 80% greater odds 
of stopping a medication in order to reduce out-of-pocket 
expenses (Spence et al 2006). Tiotropium is not available as 
a generic drug. A study of inhaled steroid use in childhood 
asthma, however, has shown that there is an SES gradient 
in use even with full medication coverage (Kozyrskyj et al 
2001). In the US as of 2007, tiotropium costs for 30-days 
of treatment were less than that of the approved-for-COPD 
concentration of combination ﬂ  uticasone/salmeterol and 
more than salmeterol alone ($134, $185, and $120, respec-
tively) (Anon 2007).
The SES gradient that we observed was apparent even 
against a background of an overall low penetration rate for 
tiotropium use, consistent with our survey taking place at 
a time when medication was relatively new on the market. 
At the time of our study only a minority of persons with 
Table 4 Tiotropium use in relation to SES: Multiple logistic regression analysis in 95 subjects
  Odds of tiotropium use in both interview and home visit
  Multivariate model includes FEV1 % predicted*  Multivariate model includes ≥COPD GOLD II*
  OR  95% CI (p value)  OR  95% CI (p value)
FEV1 % predicted† 0.5  0.3–0.9  (0.02)  NA  ------  ------
COPD GOLD II  NA  ------ ------  7.2  0.7–72.6 (0.10)
COPD Severity Score‡ 7.9  1.3–48.0  (0.02)  6.7  1.4–32.2  (0.02)
HS or income <$20,000¶ 0.01  0.001–0.5 (0.02)  0.03  0.001–0.8 (0.03)
Notes: *Multivariate models also include age, gender, and 4 overlapping respiratory disease diagnoses (COPD, emphysema, asthma, and chronic bronchitis). Nine subjects using 
tiotropium; six other subjects with discordant interview compared to home visit data for tiotropium excluded from this analysis;  †OR express per 10% change (increase) in 
FEV1 % predicted; higher % predicted associated with decreased odds of tiotropium use; ‡OR expressed per 8 point (1 SD) increase in severity score; higher severity associated 
with greater odds of tiotropium use; ¶Lower SES associated with decreased odds of tiotropium use.
Abbreviations: CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory 
volume in one second; HS, high school; SD, standard deviation; SES, socioeconomic status; OR, odds ratio.
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this COPD severity, 7 (20%) used tiotropium compared to 
2 (3.3%) of the remaining 60 subjects (p = 0.01).
Table 4 presents the results of multiple logistic regres-
sion modeling testing SES in relation to tiotropium including 
either FEV1 % predicted or GOLD  Stage II COPD along 
with all of the other independent variables previously mod-
eled. Taking either FEV1 % predicted or GOLD severity into 
account, lower SES (HS or less or annual income $20,000) 
was strongly associated with decreased odds of tiotropium 
use. Although the conﬁ  dence intervals were wide, their 
upper end is consistent with a 20%–50% decreased odds of 
tiotropium use associated with lower SES.
Discussion
We observed an SES health gradient in which lower SES 
was strongly linked to decreased odds of using tiotropium, a 
COPD medication introduced in recent years. This associa-
tion was consistently observed adjusting for age, sex, respira-
tory condition diagnoses and, most importantly, severity of 
disease. Testing additional potential confounders, including 
subspecialty care and race-ethnicity did not affect the esti-
mated SES association. Taking COPD severity into account 
is particularly critical because those with greater disease 
severity were more likely to report tiotropium use. Because 
lower SES was also linked to greater COPD severity in this 
cohort, raw differences in tiotropium use in comparisons 
unadjusted for severity were modest and not statistically 
signiﬁ  cant until this confounding factor was taken into 
account. An association between lower SES and COPD has 
been recognized by others, although disease-speciﬁ  c severity 
has not been well studied. (Mannino and Buist 2007).
The SES association with tiotropium that we observed 
may reﬂ  ect multiple factors. Although the majority of sub-
jects included in these analyses were aged 65 or older and 
thus eligible for Medicare coverage, health care access may COPD diagnoses (COPD, emphysema, or chronic bron-
chitis) were using the medication. In a population near to 
or post-retirement age, estimation of SES using survey 
research methods is challenging. In this analysis, we used 
both educational achievement and education combined with 
income as SES surrogates. We recognize, for example, that 
lower educational achievement is associated with, but does 
not predetermine lower SES. Further, relying on household 
income after retirement may attenuate SES gradients associ-
ated with differences in earnings among younger individu-
als. Moreover, COPD may lead to income loss. We did not 
assess wealth or assets in this study, which might better 
reﬂ  ect SES.
Our study has other limitations. Analysis of tiotropium 
was not a primary endpoint of the cohort study from which 
these data were drawn. In addition, we studied this question 
in a cross-sectional analysis of survey data from a time frame 
relatively soon after the introduction of tiotropium. We can-
not presume that the SES effect we observed will become 
attenuated or more marked with time as the medication 
becomes more widely prescribed over time. Pharmacoeco-
nomic analyses have supported the cost effectiveness of 
tiotropium, although recognizing that this may depend on 
willingness-to-pay criteria. (D’Souza et al 2006; Rutten-van 
Mölken et al 2007) The question of prospective trends in 
tiotropium penetration and its potential relationship to SES 
can only be addressed through longitudinal follow-up. Lung 
function was available only for a subset of subjects and we 
depended on report of a physician’s diagnosis of COPD. This 
may account, in part, for the association we observed between 
tiotropium and the reported diagnostic label of emphysema, 
which may simply be a surrogate marker for severe COPD 
rather than emphysema clearly established by physiological 
or radiographic criteria.
In our primary analyses, medication use was based 
entirely on self-report and was not conﬁ  rmed by pharmacy 
records. Thus it is possible that subjects with lower SES 
preferentially had poorer recall of tiotropium use, even in 
response to a speciﬁ  c medication checklist. Nonetheless, 
this survey approach demonstrated acceptable sensitivity 
and speciﬁ  city against direct conﬁ  rmation via home medi-
cation inspection. The SES health gradient for tiotropium, 
wherein those with lower SES may be less likely to use the 
medication, could lead to under-use among certain groups of 
patients who could particularly beneﬁ  t from such therapy. It 
may also suggest that this SES gradient may be relevant to 
other medications as they are introduced. To the extent that 
such new therapies are especially efﬁ  cacious, such gradients 
could serve to widen existing health disparities.
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